fusafungin and Bacterial-Infections

fusafungin has been researched along with Bacterial-Infections* in 4 studies

Trials

2 trial(s) available for fusafungin and Bacterial-Infections

ArticleYear
[Bioparox effects on microbiocenosis of the pharyx in patients with exacerbated pharyngitis].
    Vestnik otorinolaringologii, 2007, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Bacterial Infections; Depsipeptides; Female; Fusarium; Humans; Male; Middle Aged; Mouth Mucosa; Pharyngitis; Severity of Illness Index

2007
[Efficacy of perioperative prophylaxis with bioparox in surgical interventions on the nasal cavity and paranasal sinuses].
    Vestnik otorinolaringologii, 2006, Issue:6

    Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Combined Modality Therapy; Depsipeptides; Female; Fusarium; Humans; Male; Middle Aged; Paranasal Sinus Diseases; Postoperative Care; Preoperative Care; Prospective Studies

2006

Other Studies

2 other study(ies) available for fusafungin and Bacterial-Infections

ArticleYear
An assessment of the bacteriological activity of Locabiotal (Fusafungine) --a non-systemic antibiotic.
    The Journal of international medical research, 1977, Volume: 5, Issue:1

    Various tests were performed to establish the bacteriological potency of Locabiotal, an aerosol for local application to the nose and throat containing fusafungine. Using impregnated filter paper on a plate of solid sensitivity media considerable inhibition of the growth of common pathogens was shown. Plates of nasal swabs from adults and buccal swabs from children showed similar inhibition. Further tests after the application of the spray to the nose and throat indicated that inhibition lasts for at least eight hours.

    Topics: Adult; Aerosols; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Candidiasis; Child; Depsipeptides; Humans; Microbial Sensitivity Tests; Respiratory System; Respiratory Tract Infections

1977
A clinical assessment of locabiotal in the treatment of infections of the nose and throat.
    The Journal of international medical research, 1977, Volume: 5, Issue:2

    One hundred and twenty patients suffering from diseases of the nose and throat were admitted to an open clinical trial of the aerosol inhaler Locabiotal which contains the antibiotic fusafungine. The patient population was derived from three sources--out-patients, patients subjected to surgery and emergencies. The aerosol was administered five times daily to the throat or into the nose. The aerosol was highly effective in controlling infection and in relieving the various symptoms of the diseases treated. Variation in particle size was considered to be an advantage in penetrating various parts of the upper respiratory tract. Thirty-three patients experienced minor side-effects. These were thought to be misuse of the inhaler, or possible allergy to the antibiotic. This form of medication is recommended for a variety of diseases of the nose and throat.

    Topics: Adolescent; Adult; Aerosols; Aged; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Depsipeptides; Humans; Middle Aged; Nose Diseases; Pharyngeal Diseases; Time Factors

1977